Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA polymerase I and III subunit D (POLR1D) is a protein-coding gene encoding a key common subunit of RNA polymerase I and RNA polymerase III complexes[3]. Both complexes catalyze the DNA-dependent synthesis of ribosomal RNA (rRNA) and, for polymerase III, additional small non-coding RNAs including tRNA, snRNAs, and miRNAs[3][5]. POLR1D is essential for ribosome biogenesis and is highly expressed in embryonic tissues that will form the craniofacial skeleton[1][4]. Mutations in POLR1D disrupt rRNA production, leading to pathologies such as Treacher Collins syndrome, a rare congenital disorder characterized by craniofacial anomalies. The disease mechanism involves increased apoptosis of neural crest cells due to reduced ribosome biogenesis, with genetic evidence showing that cell death is p53-dependent in model organisms[4]. The protein is a component of the multi-subunit RNA polymerase I (13+ subunits) and polymerase III (17+ subunits) complexes[7]. There are multiple transcript variants due to alternative splicing[3]. POLR1D deficiency does not currently have drugs targeting it directly nor established mechanisms for pharmacological modulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA polymerase I and III subunit D (POLR1D).